PubMed Health⌕ Search

Biomedical subjects

Y H Chin

Publications and source records attributed to Y H Chin.

44 records · Page 3Linked to original sources

Lymphocyte recognition of lymph node high endothelium. III. Enhancement by a component of thoracic duct lymph.

The first step in the entry of blood lymphocytes into lymph node is the binding of these cells to venules lined by high endothelium (HEV). This recognition event has been studied using a model system in which rat thoracic duct lymphocytes (TDL) adhere selectively to HEV when overlaid onto lymph node sections. We now report that this binding is increased by a lymph fraction designated adherence enhancing factor (AEF). Lymph depleted of cells and chylomicra was fractionated with (NH4)2SO4. Material that precipitated between 60 and 80% saturation was dissolved in buffer and extracted with chloroform/methanol; the aqueous phase was used as the source of AEF. The factor was nondialyzable, trypsin sensitive, and heat stable (70 degrees C, 30 min). Lymph node sections pretreated with AEF showed a 2- to 3-fold increase in the number of TDL bound to HEV and a 5 to 10-fold increase in the number of HEV with more than 5 adherent lymphocytes. The effect of AEF was specific: 1) No increase in lymphocyte binding to non-HEV areas of the tissue section occurred. 2) The binding of both TDL and spleen lymphoid cells to HEV was enhanced, but thymocyte attachment was not promoted. We conclude that AEF has biologic properties that might enable it to play a physiologic role in lymphocyte recirculation.

Animals↗

Lymphocyte recognition of lymph node high endothelium. I. Inhibition of in vitro binding by a component of thoracic duct lymph.

Rat thoracic duct lymphocytes (TDL) adhere selectively to HEV when overlaid onto glutaraldehyde-fixed frozen sections of lymph node. The results presented demonstrate that thoracic duct lymph contains a factor capable of inhibiting this reaction. A crude preparation of inhibitory factor was isolated from cell and chylomicron-free lymph by (NH4)2SO4 precipitation (60 to 80% saturation). Sephacryl S-200 chromatography revealed 4 major peaks. The inhibitory factor was detected in peak I but not in the others. Similarly peak I but not peak II or III inhibited HEV binding of lymphocytes from lymph nodes and spleen. Peak I emerged near aldolase (m.w. 160,000) and was enriched approximately 50-fold compared to the crude preparation. In addition, experiments employing a rabbit peak I antiserum provided evidence that molecules responsible for inhibition were antigenically related to structures present on TDL but not on thymocytes. It is suggested that inhibitory factor possesses an affinity for lymphocyte binding sites of high endothelium and is derived from shed TDL surface components that play a role in adherence to HEV of lymph nodes.

Animals↗

Lymphocyte recognition of lymph node high endothelium. II. Characterization of an in vitro inhibitory factor isolated by antibody affinity chromatography.

Thoracic duct lymph contains a factor that inhibits in vitro adhesion between lymphocytes and high endothelial cells. Crude inhibitory factor was isolated from lymph by (NH4)2SO4 precipitation and partially purified by using an immunoabsorbant column of rabbit anti peak I Ig coupled to Sepharose 4B. Antibody affinity chromatography separated the HEV binding inhibitory factor from the bulk of protein in the crude preparation; activity was enriched 50-fold. The results show that the effect of the factor was exerted on high endothelial cells; both glutaraldehyde-fixed HEV and unfixed mouse HEV were susceptible to the action of this material. In contrast, the HEV binding properties of lymphocytes were unaffected by the factor. Inhibitory activity was destroyed by treatment with trypsin or exposure to 100 degrees C but was unaffected by incubation at 56 or 70 degrees C for 30 min. In addition, the factor bound to lentil lectin and was eluted with alpha-methyl-D-mannoside. Together these findings indicate that the HEV binding inhibitory factor is a glycoprotein.

Animals↗

The significance of body weight change in non-Hodgkins lymphoma.

BACKGROUND: The purpose of this study was to evaluate the effect of weight changes after completion of chemotherapy on the prognosis and survival of patients with intermediate and high grade non-Hodgkin's lymphoma. MATERIALS AND METHODS: A retrospective analysis of data on patients from the TCOG T1488 protocol, a phase II study using CHOP in the treatment of intermediate and high grade lymphoma. From September, 1988 to December 1994, 138 adult patients had complete weight data for analysis. Weight gain in lymphoma patients after therapy significantly correlated with improved survival (Logrank test p = .0031). In patients with initial B symptoms, weight gain after therapy correlated with survival (Logrank test p = .0039), female patients (odds ratio = 6.2) were less likely to gain weight on treatment. CONCLUSION: Weight gain after chemotherapy for lymphoma is a significant positive prognostic factor for survival.

Adult↗

Specific lymphocyte-endothelial cell interactions regulate migration into lymph nodes, Peyer's patches, and skin.

Lymphocyte migration is a critical component of a functional immune system. It increases the efficiency of the regional immune responses and disseminates locally induced effector cells to distant inflammatory sites. Central to the migratory process is the ability of lymphocytes to extravasate from the blood by selectively binding to segments of venules lined by high endothelium in lymph nodes and mucosal-associated lymphoid tissues. Recent studies have demonstrated that the specific recognition and adhesion of lymphocytes to high endothelial venules (HEV) is mediated by receptor/ligand systems that are different between lymph nodes (LN) and Peyer's patches (PP). The differential expression of lymphocyte surface receptors accounts for the preferential migration patterns of distinct lymphocyte subsets. More recently, the existence of specialized dermal endothelial cells in cutaneous tumors and inflamed skin that are capable of supporting lymphocyte adherence has been documented. This lymphocyte-endothelial cell interaction is an energy- and calcium-dependent process that involves surface glycoprotein and carbohydrates, requirements that are analogous to lymphocyte binding to HEV in LN and PP. Interestingly, antibodies directed against surface molecules mediating adhesion to HEV of LN and HEV of PP have no effect on lymphocyte binding to the dermal endothelium, suggesting that an additional receptor/ligand system promotes lymphocyte traffic into this site. Moreover, similar but additional receptor/ligand interactions may exist and may mediate lymphocyte migration into other sites. The identification and isolation of these receptor/ligand systems will provide important insights into both regional specialization of the normal immune response and pathophysiology of inflammatory diseases in diverse organs and tissues.

Animals↗